| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 18,900 | 16,890 | 17,390 | 15,680 | 16,260 |
| Sales Growth | +11.90% | -2.88% | +10.91% | -3.57% | +10.84% |
| Net Income | 2,760 | 2,140 | 2,200 | 1,890 | 1,970 |
| Net Income Growth | +28.97% | -2.73% | +16.40% | -4.06% | +34.01% |
Electromed Inc (ELMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Electromed, Inc. manufactures, markets and sells products that provide airway clearance therapy to patients with compromised pulmonary function. The Company is the designer, manufacturer and worldwide provider of the SmartVest' Airway Clearance System and related products. The patented system uses High Frequency Chest Wall Oscillation (HFCWO), an alternative to Chest Physiotherapy (CPT), to deliver airway clearance treatment. The Company manufactures its products for use by chronically-ill patients who face health risks due to pneumonia and mucus accumulation in the lungs, particularly patients with cystic fibrosis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and neuro-muscular disorders. The purpose of its primary product, the SmartVest System, is to loosen, mobilize, and release respiratory secretions from the lungs. The Company's products are primarily used in the home health care market and in hospitals. Electromed, Inc. is headquartered in New Prague, Minnesota.
Fiscal Year End Date: 06/30